Kohzoh Imai

Yokohama, 2418515, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 88 publications

Determinants of Efficacy and Optimization of Chimeric Antigen Receptor T-Cell Therapy for Treating Multiple Myeloma: Current Status and Future Perspectives.

Determinants of Efficacy and Optimization of Chimeric Antigen Receptor T-Cell Therapy for Treating Multiple Myeloma: Current Status and Future Perspectives.

Journal: Cells

Published: January 08, 2026

Therapeutic Antibodies in Hematology: Advances in Malignant and Non-Malignant Disorders.

Therapeutic Antibodies in Hematology: Advances in Malignant and Non-Malignant Disorders.

Journal: Cells

Published: December 02, 2025

Mechanistic insights into the limited function of CAR-T cells in solid tumors and potential solutions.

Mechanistic insights into the limited function of CAR-T cells in solid tumors and potential solutions.

Journal: International immunopharmacology

Published: April 17, 2025

Improvement in the function of self-activating chimeric antigen receptor by replacing the linker sequence.

Improvement in the function of self-activating chimeric antigen receptor by replacing the linker sequence.

Journal: Frontiers in immunology

Published: September 27, 2024

Chondroitin sulfate proteoglycan 4: An attractive target for antibody-based immunotherapy.

Chondroitin sulfate proteoglycan 4: An attractive target for antibody-based immunotherapy.

Journal: Proceedings of the Japan Academy. Series B, Physical and biological sciences

Published: May 12, 2024

Novel chimeric antigen receptor-expressing T cells targeting the malignant mesothelioma-specific antigen sialylated HEG1.

Novel chimeric antigen receptor-expressing T cells targeting the malignant mesothelioma-specific antigen sialylated HEG1.

Journal: International journal of cancer

Published: June 12, 2023

Medical application of the monoclonal antibody SKM9-2 against sialylated HEG1, a new precision marker for malignant mesothelioma.

Medical application of the monoclonal antibody SKM9-2 against sialylated HEG1, a new precision marker for malignant mesothelioma.

Journal: Proceedings of the Japan Academy. Series B, Physical and biological sciences

Published: February 12, 2023

Therapeutic siRNA targeting the cancer cell stemness regulator PRDI-BF1 and RIZ domain zinc finger protein 14.

Therapeutic siRNA targeting the cancer cell stemness regulator PRDI-BF1 and RIZ domain zinc finger protein 14.

Journal: Proceedings of the Japan Academy. Series B, Physical and biological sciences

Published: July 31, 2022

Antitumoral RNA-targeted oligonucleotide therapeutics: The third pillar after small molecule inhibitors and antibodies.

Antitumoral RNA-targeted oligonucleotide therapeutics: The third pillar after small molecule inhibitors and antibodies.

Journal: Cancer science

Published: February 09, 2022

Membranous HEG1 expression is a useful marker in the differential diagnosis of epithelioid and biphasic malignant mesothelioma versus carcinomas.

Membranous HEG1 expression is a useful marker in the differential diagnosis of epithelioid and biphasic malignant mesothelioma versus carcinomas.

Journal: Pathology international

Published: January 11, 2021

Treatment of primary and metastatic breast and pancreatic tumors upon intravenous delivery of a PRDM14-specific chimeric siRNA/nanocarrier complex.

Treatment of primary and metastatic breast and pancreatic tumors upon intravenous delivery of a PRDM14-specific chimeric siRNA/nanocarrier complex.

Journal: International journal of cancer

Published: August 07, 2020

Microsatellite instability in cancer: a novel landscape for diagnostic and therapeutic approach.

Microsatellite instability in cancer: a novel landscape for diagnostic and therapeutic approach.

Journal: Archives of toxicology

Published: April 28, 2020

Showing 1-12 of 88

Last Updated: 09/26/2026